Private company
DURECT CORP
American pharmaceutical preparations company based in Cupertino. Summary from the record
Last updated Oct 19, 2026.
Overview
- IndustryPharmaceutical Preparations2
- HeadquartersCupertino, United States2
- Incorporated inDE3
- Business address10240 Bubb Road, Cupertino, Ca 950143
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300EW9IYW3V3QPJ862
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O UNITED AGENT GROUP INC., 19803 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 28562672
See how the biggest companies compare on our leaderboards
DURECT Corporation (the “Company,” “DURECT,” “we,” “us” and “our”) is a biopharmaceutical company advancing novel and potentially lifesaving investigational therapies derived from our Epigenetic Regulator Program. Larsucosterol, a new chemical entity in clinical development, is the lead candidate in our Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play an important regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. We are developing larsucosterol for alcohol-associated hepatitis (“AH”), a life-threatening acute liver condition with no approved therapeutics and 28-Day and 90-Day historical mortality rates of 20%-26% and 29%-31%, respectively. After completing a Phase 2a trial in which 100% of AH patients treated with larsucosterol survi…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue0¢$78.0K
- Research and development50¢$10.4M
- Selling, general and admin50¢$10.5M
Out of $2.0M in revenue.5 The company lost money this year.
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $15.3M6 | $25.1M7 | $30.1M8 | $14.0M9 | $19.3M9 | $2.6M5 | $2.0M5 |
| Cost of revenue | $1.6M6 | $1.3M7 | $1.4M8 | $2.0M9 | $1.6M9 | $268.0K5 | $78.0K5 |
| Research and development | $25.0M6 | $29.6M7 | $27.7M8 | $31.8M9 | $36.9M9 | $29.4M5 | $10.4M5 |
| Selling, general and admin | $12.3M6 | $14.1M7 | $13.6M8 | $14.4M9 | $15.9M9 | $12.7M5 | $10.5M5 |
| Operating expenses | $48.2M9 | $54.4M9 | $42.3M5 | $20.9M5 | |||
| Operating income | -$23.6M6 | -$19.9M7 | -$12.6M8 | -$34.3M9 | -$35.1M9 | -$39.7M5 | -$18.9M5 |
| Interest | $2.6M6 | $2.5M7 | $2.2M8 | $2.1M8 | $2.4M8 | ||
| Income tax | $09 | $09 | $05 | $05 | |||
| Net income | -$25.3M6 | -$20.6M7 | -$582.0K8 | -$36.3M9 | -$35.3M9 | -$27.6M5 | -$8.3M5 |
| Earnings per share | -$0.166 | -$0.127 | -$0.038 | -$1.619 | -$1.559 | -$1.055 | -$0.275 |
| Earnings per share (diluted) | -$0.166 | -$0.127 | -$0.038 | -$1.619 | -$1.559 | -$1.205 | -$0.275 |
| Shares (weighted, basic) | 22.5M shares9 | 22.8M shares9 | 26.3M shares5 | 30.9M shares5 | |||
| Shares (weighted, diluted) | 22.5M shares9 | 22.8M shares9 | 26.5M shares5 | 30.9M shares5 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $31.6M12 | $34.9M6 | $21.3M7 | $49.8M8 | $43.5M9 | $28.4M5 | $11.0M5 |
| Receivables | $6.5M8 | $3.4M9 | $618.0K5 | $453.0K5 | |||
| Inventory | $1.9M8 | $2.1M9 | $132.0K5 | $106.0K5 | |||
| Current assets | $41.7M12 | $71.8M6 | $63.1M7 | $81.7M8 | $51.4M9 | $34.7M5 | $13.2M5 |
| Property, plant and equipment | $227.0K8 | $188.0K9 | $88.0K5 | $41.0K5 | |||
| Goodwill | $6.2M8 | $6.2M9 | $6.2M5 | $2.7M5 | |||
| Total assets | $50.0M12 | $86.0M6 | $75.6M7 | $92.0M8 | $60.1M9 | $45.2M5 | $18.3M5 |
| Accounts payable | $1.3M8 | $3.1M9 | $1.7M5 | $309.0K5 | |||
| Short-term debt | $21.2M9 | $16.7M5 | $05 | ||||
| Current liabilities | $7.7M12 | $36.8M6 | $10.7M7 | $10.1M8 | $34.0M9 | $27.0M5 | $7.7M5 |
| Long-term debt | $20.5M12 | $20.3M6 | $19.9M7 | $20.6M8 | $21.2M8 | $16.7M9 | |
| Retained earnings | -$526.0M8 | -$561.4M9 | -$589.0M5 | -$597.3M5 | |||
| Shareholders’ equity | $20.0M7 | $22.9M8 | $40.1M9 | $57.8M9 | $25.0M5 | $14.8M5 | $9.1M5 |
| Shares outstanding | 162.1M shares12 | 195.3M shares6 | 203.5M shares7 | 22.8M shares8 | 22.8M shares9 | 30.3M shares5 | 31.0M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$19.8M6 | $11.1M7 | -$38.7M8 | -$37.3M9 | -$26.3M9 | -$34.4M5 | -$19.1M5 |
| Depreciation and amortization | $288.0K9 | $119.0K9 | $31.0K5 | $84.0K5 | |||
| Stock-based compensation | $2.7M9 | $2.5M9 | $2.5M5 | $2.0M5 | |||
| Capital spending | $93.0K6 | $155.0K7 | $208.0K8 | $194.0K9 | $111.0K9 | $52.0K5 | $05 |
| Free cash flow | -$19.8M | $10.9M | -$38.9M | -$37.5M | -$26.4M | -$34.5M | -$19.1M |
| Cash from investing | $15.3M9 | $19.8M9 | -$1.2M5 | $18.0M5 | |||
| Cash from financing | $50.5M9 | $83.0K9 | $20.5M5 | -$16.3M5 |
Leadership
Who has led DURECT CORP, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
- ChairFelix Theeuwes Jan 10, 2006 to Jan 30, 201813
- Chief financial officerTimothy M. Papp Jul 5, 2022 to now14
- Chief financial officerMichael Arenberg Oct 17, 2018 to Jan 10, 202215
- Chief financial officerMatthew J. Hogan Sep 12, 2006 to Jan 30, 201816
Board members and other officers (21)
- Chief Medical OfficerNorman Sussman Nov 4, 2020 to now17
- Sr. VP Operations & Corp QAJudy R. Joice Apr 10, 2014 to Feb 23, 202318
- CMO and Exec.VP Corp. StrategyJoseph William Stauffer Jun 17, 2009 to Jan 21, 201119
- VP Pharmaceutical R&DAndrew Miksztal Jan 3, 2006 to Jan 10, 200620
- VP Finance & Corp. ControllerLi Jian Jan 10, 2006 to Mar 25, 202221
- Sr. VP of OperationsPaula Mendenhall V. Jan 10, 2006 to Feb 7, 201222
- VP Clinical and RegulatorySteven Halladay Jan 10, 2006 to Jan 10, 200623
- Sr. VP EngineeringSu Il Yum Jan 10, 2006 to Jan 13, 201524
- Chief Medical OfficerPeter Langecker May 2, 2006 to May 26, 200925
- Board memberGail J. Maderis Jan 5, 2021 to now26
- Board memberMohammad Azab Jan 5, 2021 to now27
- Board memberPeter S. Garcia Dec 14, 2021 to now28
- Board memberGail M. Farfel Apr 25, 2019 to now29
- Board memberJudith J. Robertson Apr 25, 2019 to now30
- Board memberJay Shepard Sep 30, 2013 to Jun 23, 201631
- Board memberArmand Neukermans Jun 21, 2006 to Jun 18, 202032
- Board memberJon S. Saxe Jun 21, 2006 to Jun 18, 202033
- Board memberSimon X. Benito Jun 21, 2006 to Dec 9, 202134
- Board memberMichael D. Casey Jun 22, 2006 to Jun 26, 201335
- Board memberTerrence F. Blaschke Dec 18, 2006 to now36
- General counselJean I. Liu Jan 10, 2006 to Jul 13, 201137
Timeline
- Feb 6, 1998Founded DURECT CORP is founded2
Filings
224 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 61 major events, 74 insider forms, 13 large holders, 60 other. The latest 20:
- Sep 22, 202515-12G EDGAR
- Sep 16, 20254/A EDGAR
- Sep 12, 2025EFFECT EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 12, 20254 EDGAR
- Sep 11, 202525-NSE EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
- Sep 11, 2025S-8 POS EDGAR
The 224 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
25 open-market trades by officers, directors and large owners since October 2021: 24 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | ASEN R SCOTT10% owner | Buy | 5,917 | $1.92 | $11.4K | Form 4 |
| Aug 21, 2025 | ASEN R SCOTT10% owner | Buy | 116,612 | $1.90 | $221.6K | Form 4 |
| Aug 20, 2025 | ASEN R SCOTT10% owner | Buy | 87,608 | $1.89 | $165.6K | Form 4 |
| Aug 19, 2022 | Robertson Judith J.Director | Buy | 9,412 | $0.85 | $8.0K | Form 4 |
| Aug 18, 2022 | Robertson Judith J.Director | Buy | 71,531 | $0.85 | $60.8K | Form 4 |
| Aug 17, 2022 | Robertson Judith J.Director | Buy | 10,189 | $0.85 | $8.6K | Form 4 |
| Aug 12, 2022 | Maderis Gail JDirector | Buy | 25,204 | $0.71 | $17.9K | Form 4 |
| Aug 11, 2022 | Maderis Gail JDirector | Buy | 24,796 | $0.70 | $17.4K | Form 4 |
| Aug 10, 2022 | Maderis Gail JDirector | Buy | 79,693 | $0.69 | $55.0K | Form 4 |
| Aug 9, 2022 | Maderis Gail JDirector | Buy | 70,307 | $0.64 | $45.0K | Form 4 |
| May 26, 2022 | Robertson Judith J.Director | Buy | 65,000 | $0.39 | $25.4K | Form 4 |
| May 24, 2022 | AZAB MOHAMMADDirector | Buy | 30,000 | $0.39 | $11.7K | Form 4 |
| May 18, 2022 | Farfel Gail MDirector | Buy | 29,911 | $0.41 | $12.3K | Form 4 |
| May 17, 2022 | AZAB MOHAMMADDirector | Buy | 20,000 | $0.42 | $8.4K | Form 4 |
| May 16, 2022 | Farfel Gail MDirector | Buy | 25,300 | $0.39 | $9.9K | Form 4 |
| May 16, 2022 | AZAB MOHAMMADDirector | Buy | 10,000 | $0.38 | $3.8K | Form 4 |
| May 13, 2022 | Farfel Gail MDirector | Buy | 9,250 | $0.40 | $3.7K | Form 4 |
| May 12, 2022 | Farfel Gail MDirector | Buy | 1,500 | $0.39 | $585 | Form 4 |
| May 11, 2022 | Farfel Gail MDirector | Buy | 9,950 | $0.40 | $4.0K | Form 4 |
| May 10, 2022 | Farfel Gail MDirector | Buy | 2,339 | $0.41 | $959 | Form 4 |
All 25 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- INGALLS & SNYDER LLCSCHEDULE 13G/A, 2 filings Mar 27, 2024 to Feb 21, 202538
- R. Scott AsenSCHEDULE 13G/A, 3 filings Feb 16, 2024 to Jan 8, 202539
- Lion Point Capital, LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202440
- Bleichroeder LPSC 13G/A, 2 filings Feb 14, 2023 to Dec 1, 202341
- VANGUARD GROUP INCSC 13G/A, 1 filing Feb 9, 202242
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARDURECT CORP filings on SEC EDGAR
- 2
- 3SEC EDGARDURECT CORP filings on SEC EDGAR
- 4
- 5SEC EDGARDURECT CORP 10-K for fiscal 2024
- 6SEC EDGARDURECT CORP 10-K for fiscal 2018
- 7SEC EDGARDURECT CORP 10-K for fiscal 2019
- 8SEC EDGARDURECT CORP 10-K for fiscal 2020
- 9SEC EDGARDURECT CORP 10-K for fiscal 2021
- 10SEC EDGARDURECT CORP 10-Q for fiscal 2025
- 11SEC EDGARDURECT CORP 10-Q for fiscal 2025
- 12SEC EDGARDURECT CORP 10-K for fiscal 2018
- 13SEC EDGARFelix Theeuwes, Chair
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGARSu Il Yum, Sr. VP Engineering
- 25
- 26SEC EDGARGail J. Maderis, Board member
- 27SEC EDGARMohammad Azab, Board member
- 28SEC EDGARPeter S. Garcia, Board member
- 29SEC EDGARGail M. Farfel, Board member
- 30SEC EDGARJudith J. Robertson, Board member
- 31SEC EDGARJay Shepard, Board member
- 32SEC EDGARArmand Neukermans, Board member
- 33SEC EDGARJon S. Saxe, Board member
- 34SEC EDGARSimon X. Benito, Board member
- 35SEC EDGARMichael D. Casey, Board member
- 36SEC EDGARTerrence F. Blaschke, Board member
- 37SEC EDGARJean I. Liu, General counsel
- 38
- 39
- 40
- 41
- 42